Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction.

导出 OA

翻译打印收藏纠错

作者： Bart J,van Essen ^[1] ; Jasper,Tromp ^[1] ; Jozine M,Ter Maaten ^[2] ; Barry H,Greenberg ^[3] ; Claudio,Gimpelewicz ^[1] ; G Michael,Felker ^[4] ; Beth A,Davison ^[5] ; Thomas,Severin ^[6] ; Peter S,Pang ^[7] ; Gad,Cotter ^[8] ; John R,Teerlink ^[5] ; Marco,Metra ^[9] ; Adriaan A,Voors ^[7]

作者单位： Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. ^[1] Saw Swee Hock School of Public Health, National University of Singapore & the National University Health System, Singapore. ^[2] Duke-NUS Medical School, Singapore. ^[3] University of California San Diego, San Diego, CA, USA. ^[4] Novartis Pharma, Basel, Switzerland. ^[5] Division of Cardiology, Duke University School of Medicine, Durham, NC, USA. ^[6] Momentum Research Inc., Chapel Hill, NC, USA. ^[7] Inserm U 942 (MASCOT), Hopital Lariboisière, Paris, France. ^[8] Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. ^[9] Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, CA, USA. ^[10] Cardiology, Department of Medical and Surgical Specialties, Radiologic Sciences, and Public Health, University of Brescia, Brescia, Italy. ^[11]

关键词 Acute heart failure Clinical outcome Heart failure with supranormal ejection fraction Serelaxin